Defining Stress REsilience And Mindfulness Effects in Rheumatoid Arthritis
| 対象疾患 | Arthritis, Rheumatoid |
|---|---|
| 相 | 該当なし |
| スポンサー | University of California, San Francisco |
| ステータス | 完了 |
| 参加者数 | 38 名 |
| 介入（薬剤） | Mindfulness Program |
| 開始日 | 2024年1月26日 |
| 完了日 | 2025年1月1日 |
| 結果公開日 | 2026年5月22日 |
概要
This clinical trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The main goals of this pilot study are to: * Assess patient satisfaction with a mindfulness course * Identify barriers to participation in, or completion of, a mindfulness course * Gather initial information to understand how a mindfulness course impacts RA symptoms Participants will: * Complete online questionnaires * Attend two in-person study visits, involving a brief joint exam and blood draw * Roughly half the participants will have the chance to participate in an 8-week online mindfulness course * Roughly half the participants will be invited to participate in an online focus group following completion of the mindfulness course Researchers will compare those in the mindfulness course with those receiving standard care in preparation for a larger future study to see how mindfulness impacts stress and inflammation in individuals with RA.
Patient Satisfaction as Assessed by CSQ-8, Adapted for DREAMER Study
| Mindfulness-based Stress Reduction for Rheumatic Diseases (MBSR-RD) | 14 Participants |
|---|---|
| Treatment as Usual (TAU) | 0 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company